London Bridge Hospital

About: London Bridge Hospital is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Antiphospholipid syndrome & Systemic lupus erythematosus. The organization has 107 authors who have published 122 publications receiving 4523 citations.

Hughes syndrome (antiphospholipid syndrome)

Abstract: An increasingly important link between aPL antibodies and a clinical syndrome is becoming recognized worldwide. This syndrome, known as the antiphospholipid syndrome (APS) or Hughes syndrome, is a prothrombotic disorder leading to both arterial and venous thrombosis and, in pregnancy, recurrent abortion and pregnancy loss (Figure 13.1).

Diagnosing Thoracic Outlet Syndrome: Current Approaches and Future Directions

Abstract: The diagnosis of thoracic outlet syndrome (TOS) has long been a controversial and challenging one. Despite common presentations with pain in the neck and upper extremity, there are a host of presenting patterns that can vary within and between the subdivisions of neurogenic, venous, and arterial TOS. Furthermore, there is a plethora of differential diagnoses, from peripheral compressive neuropathies, to intrinsic shoulder pathologies, to pathologies at the cervical spine. Depending on the subdivision of TOS suspected, diagnostic investigations are currently of varying importance, necessitating high dependence on good history taking and clinical examination. Investigations may add weight to a diagnosis suspected on clinical grounds and suggest an optimal management strategy, but in this changing field new developments may alter the role that diagnostic investigations play. In this article, we set out to summarise the diagnostic approach in cases of suspected TOS, including the importance of history taking, clinical examination, and the role of investigations at present, and highlight the developments in this field with respect to all subtypes. In the future, we hope that novel diagnostics may be able to stratify patients according to the exact compressive mechanism and thereby suggest more specific treatments and interventions.

Comparison of hamstring/quadriceps isokinetic strength ratios and power in tennis, squash and track athletes.

Abstract: Isokinetic assessment of elite squash, tennis and track athletes confirms the accepted ratio of 60 to 80 per cent hamstring to quadriceps when testing at 90 deg-sec-1 for peak strength (torque). However, significant variations occur at higher test speeds up to 300 deg.sec-1 with the hamstrings becoming more prominent especially (p less than 0.001) in the nonpreferred (NP) leg. There was no significant difference between sports, and wide individual differences occurred. Analysis of (work.sec-1.kg-1 body weight) power showed a significantly higher work output (p less than 0.01) by track athletes than squash and tennis players, but, unlike hamstring/quadriceps ratio, no significant difference between preferred (P) and nonpreferred leg. The maximum power output was achieved around 220 to 250 deg.sec-1. Power between preferred and nonpreferred legs was the same but the torque ratio differed indicating that the hamstrings provided proportionately more work in the NP leg at higher speeds.

Testosterone treatment is not associated with increased risk of adverse cardiovascular events: results from the Registry of Hypogonadism in Men (RHYME).

Abstract: SummaryAims The aim of this study was to assess cardiovascular (CV) safety of testosterone replacement therapy (TRT) in a large, diverse cohort of European men with hypogonadism (HG). Methods The Registry of Hypogonadism in Men (RHYME) was designed as a multi-national, longitudinal disease registry of men diagnosed with hypogonadism (HG) at 25 clinical sites in six European countries. Data collection included a complete medical history, physical examination, blood sampling and patient questionnaires at multiple study visits over 2–3 years. Independent adjudication was performed on all mortalities and CV outcomes. Results Of 999 patients enrolled with clinically diagnosed HG, 750 (75%) initiated some form of TRT. Registry participants, including both treated and untreated patients, contributed 23 900 person-months (99.6% of the targeted) follow-up time. A total of 55 reported CV events occurred in 41 patients. Overall, five patients died of CV-related causes (3 on TRT, 2 untreated) and none of the deaths were adjudicated as treatment-related. The overall CV incidence rate was 1522 per 100 000 person-years. CV event rates for men receiving TRT were not statistically different from untreated men (P=.70). Regardless of treatment assignment, CV event rates were higher in older men and in those with increased CV risk factors or a prior history of CV events. Conclusions Age and prior CV history, not TRT use, were predictors of new-onset CV events in this multi-national, prospective hypogonadism registry.